Curis (NASDAQ:CRIS) Now Covered by StockNews.com

StockNews.com began coverage on shares of Curis (NASDAQ:CRIS) in a research report sent to investors on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Curis in a research note on Tuesday, December 10th.

Curis Stock Performance

Shares of NASDAQ CRIS opened at $2.66 on Friday. The firm has a fifty day moving average of $3.12 and a 200 day moving average of $3.97. The firm has a market cap of $22.52 million, a PE ratio of -0.34 and a beta of 3.49. Curis has a one year low of $2.57 and a one year high of $17.49.

Institutional Trading of Curis

Large investors have recently made changes to their positions in the company. Focused Wealth Management Inc lifted its holdings in Curis by 9.5% in the 4th quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock valued at $181,000 after purchasing an additional 5,138 shares in the last quarter. CM Management LLC lifted its stake in shares of Curis by 83.3% in the fourth quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock worth $673,000 after buying an additional 100,000 shares in the last quarter. Geode Capital Management LLC boosted its position in Curis by 27.3% during the fourth quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock worth $254,000 after acquiring an additional 17,820 shares during the last quarter. M28 Capital Management LP grew its stake in Curis by 23.5% during the 4th quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock valued at $1,594,000 after acquiring an additional 99,108 shares in the last quarter. Finally, Samsara BioCapital LLC purchased a new stake in Curis during the 4th quarter valued at about $607,000. 29.97% of the stock is currently owned by hedge funds and other institutional investors.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.